Skip to main content
Premium Trial:

Request an Annual Quote

Gene-Editing Startup Exonics Therapeutics Receives $5M From CureDuchenne Ventures

NEW YORK (GenomeWeb) – CureDuchenne Ventures has provided $5 million in seed financing to Exonics Therapeutics, a new firm exploring the use of CRISPR/Cas9 in the development of new treatments for Duchenne muscular dystrophy (DMD).

Exonics said in a statement that it will use the proceeds to advance preclinical research from the lab of founder Eric Olson using adeno-associated viruses to deliver CRISPR to cells in order to identify and correct exon mutations in DMD patients. Olson is also a professor and researcher at the University of Texas-Southwestern Medical Center whose work on correcting DMD mutations with CRISPR/Cas9 has led to improvement in a live animal model of the disease.

CureDuchenne Ventures is a subsidiary of the non-profit CureDuchenne, which seeks to improve the standard of care and living of boys with DMD, a genetic disease that hampers the production of the muscle fiber protein dystrophin. The group collaborates with biotech firms to develop therapies for DMD.

"Exonics' CRISPR/Cas9 technology has the potential to dramatically improve the lives of those who live with Duchenne," CureDuchenne CEO Debra Miller said in a statement. "We are hopeful that a one-time treatment with gene editing therapy could provide a lifelong benefit to Duchenne patients."

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.